Trends in and Predictors of Patient Pharmacogenomic Test Uptake in a National Healthcare System.

IF 6.6 1区 医学 Q1 GENETICS & HEREDITY
Abigail Silva, Deepak Voora, Rebekah Ryanne Wu, Brian Bartle, Catherine Chanfreau-Coffinier, Allison Hung, Corrine I Voils
{"title":"Trends in and Predictors of Patient Pharmacogenomic Test Uptake in a National Healthcare System.","authors":"Abigail Silva, Deepak Voora, Rebekah Ryanne Wu, Brian Bartle, Catherine Chanfreau-Coffinier, Allison Hung, Corrine I Voils","doi":"10.1016/j.gim.2024.101308","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Better understanding patient uptake of pharmacogenomic (PGx) testing may inform its implementation and maximize the benefits that such testing can confer. This study examined patient and provider factors associated with PGx test ordering in a national healthcare system where panel-based testing was implemented as part of routine care.</p><p><strong>Methods: </strong>We used a retrospective matched cohort design and data from the Veterans Health Administration Corporate Data Warehouse. A conditional logistic model was used to identify factors associated with a PGx order receipt and estimate odds ratios and 95% confidence intervals.</p><p><strong>Results: </strong>The following patient factors predicted receipt of a PGx test order: younger age, married status, rural residence, non-Hispanic Black or Hispanic race/ethnicity, PGx educational mailer receipt, depression diagnosis, allergy to a drug on the panel, prescriptions for drugs on the panel, and specialty care visits (p<0.05). Additionally, patients whose providers were female, younger, a nurse practitioner/physician assistant or pharmacist, or participated in an educational mailer program were more likely to receive an order (p<0.05).</p><p><strong>Conclusion: </strong>This study highlights factors that may facilitate or hinder the widespread and equitable implementation of PGx testing in a large national healthcare system. The information is being used to further refine the program.</p>","PeriodicalId":12717,"journal":{"name":"Genetics in Medicine","volume":null,"pages":null},"PeriodicalIF":6.6000,"publicationDate":"2024-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Genetics in Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.gim.2024.101308","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GENETICS & HEREDITY","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: Better understanding patient uptake of pharmacogenomic (PGx) testing may inform its implementation and maximize the benefits that such testing can confer. This study examined patient and provider factors associated with PGx test ordering in a national healthcare system where panel-based testing was implemented as part of routine care.

Methods: We used a retrospective matched cohort design and data from the Veterans Health Administration Corporate Data Warehouse. A conditional logistic model was used to identify factors associated with a PGx order receipt and estimate odds ratios and 95% confidence intervals.

Results: The following patient factors predicted receipt of a PGx test order: younger age, married status, rural residence, non-Hispanic Black or Hispanic race/ethnicity, PGx educational mailer receipt, depression diagnosis, allergy to a drug on the panel, prescriptions for drugs on the panel, and specialty care visits (p<0.05). Additionally, patients whose providers were female, younger, a nurse practitioner/physician assistant or pharmacist, or participated in an educational mailer program were more likely to receive an order (p<0.05).

Conclusion: This study highlights factors that may facilitate or hinder the widespread and equitable implementation of PGx testing in a large national healthcare system. The information is being used to further refine the program.

全国医疗保健系统中患者药物基因组学测试接受趋势和预测因素。
目的:更好地了解患者对药物基因组学(PGx)检测的接受程度可为其实施提供依据,并最大限度地发挥此类检测所能带来的益处。本研究考察了在一个全国性医疗保健系统中,患者和医疗服务提供者与订购 PGx 检测相关的因素:我们采用了回顾性匹配队列设计,数据来自退伍军人健康管理局企业数据仓库。我们使用条件逻辑模型来确定与收到 PGx 订单相关的因素,并估算出几率比和 95% 的置信区间:结果:以下患者因素可预测是否收到 PGx 检验订单:年龄较小、已婚、农村居民、非西班牙裔黑人或西班牙裔种族/民族、收到 PGx 教育邮件、抑郁症诊断、对面板上的药物过敏、面板上的药物处方以及专科护理就诊(P结论:该研究强调了可能促进 PGx 检验订单的因素,并估算了几率比和 95% 的置信区间:本研究强调了可能促进或阻碍在大型国家医疗保健系统中广泛、公平地实施 PGx 检验的因素。这些信息将用于进一步完善该计划。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Genetics in Medicine
Genetics in Medicine 医学-遗传学
CiteScore
15.20
自引率
6.80%
发文量
857
审稿时长
1.3 weeks
期刊介绍: Genetics in Medicine (GIM) is the official journal of the American College of Medical Genetics and Genomics. The journal''s mission is to enhance the knowledge, understanding, and practice of medical genetics and genomics through publications in clinical and laboratory genetics and genomics, including ethical, legal, and social issues as well as public health. GIM encourages research that combats racism, includes diverse populations and is written by authors from diverse and underrepresented backgrounds.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信